Renal Cancer Drug Can Be Used as Treatment for MesotheliomaTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Franz, F. (2021, September 14). Renal Cancer Drug Can Be Used as Treatment for Mesothelioma. Asbestos.com. Retrieved February 1, 2023, from https://www.asbestos.com/news/2011/05/12/renal-cancer-drug-can-be-used-as-new-treatment-for-mesothelioma/
Franz, Faith. "Renal Cancer Drug Can Be Used as Treatment for Mesothelioma." Asbestos.com, 14 Sep 2021, https://www.asbestos.com/news/2011/05/12/renal-cancer-drug-can-be-used-as-new-treatment-for-mesothelioma/.
Franz, Faith. "Renal Cancer Drug Can Be Used as Treatment for Mesothelioma." Asbestos.com. Last modified September 14, 2021. https://www.asbestos.com/news/2011/05/12/renal-cancer-drug-can-be-used-as-new-treatment-for-mesothelioma/.
In a study published in the May issue of the Journal of Thoracic Oncology, temsirolimus, a drug that is used to treat kidney cancer, has shown positive results when treating pleural mesothelioma cells.
Temsirolimus is a kinase inhibitor, which blocks the growth of mammalian target of rapamycin (mTOR) proteins. These proteins are found in the cancer’s cells.
Malignant mesothelioma, an uncommon form of cancer that develops in the lining of the vital organs in the body, is directly linked to asbestos exposure.
Because of the long latency period associated with the cancer, it is frequently not diagnosed until the late stages of the disease.
Temsirolimus as a Second-Line Treatment
Temsirolimus had a strong growth-stopping effect on all cancer cells. However, cisplatin, a commonly used chemotherapy drug for asbestos cancer treatment, displayed hypersensitivity against temsirolimus.
Because of this, researchers in the study believe temsirolimus can be used in combination with other current chemotherapeutic treatments as a second-line treatment.
Professor Walter Berger of the Institute of Cancer Research at the Medical University of Vienna, a researcher on the project, stated, “Malignant mesothelioma is a severe human malignancy characterized by a very bad prognosis, with a mean patient survival of less than one year. This unacceptable situation is mainly caused by late diagnosis combined with a distinct resistance to all forms of systemic therapy available so far.”
Professor Berger commented further on the results of the study saying, “In our preclinical study, published in the JTO, we were able to demonstrate that the inhibition of the major oncogene mTOR is activate against human mesothelioma especially after development of chemotherapy resistance both in vitro and in vivo. These results suggest the initiation of clinical trials involving mTOR inhibitors as novel anti-mesothelioma strategy.”